News | Myriad Genetics

Myriad Genetics to Present at the 2017 JP Morgan Healthcare Conference

Dec 28, 2016 | Corporate

Positive Clinical Utility Results of Crescendo's Vectra® DA Test for Rheumatoid Arthritis Published in the Journal Arthritis & Rheumatology

Dec 27, 2016 | Products

United Rheumatology Issues Clinical Practice Guidelines and Recommends the Vectra® DA Test for Adults with Rheumatoid Arthritis

Dec 22, 2016 | Products

The EndoPredict® Test Significantly Outperforms the First-Generation Test in Predicting the Risk of Node-Negative and Node-Positive Breast Cancer Recurrence

Dec 09, 2016 | Products

Myriad Genetics Will Present Results from Six Breast Cancer Studies at SABCS

Nov 28, 2016 | Products

Crescendo Bioscience Announces Four Studies with Vectra® DA Will Be Presented at the American College of Rheumatology 2016 Annual Meeting

Nov 12, 2016 | Products

Myriad Will Seek Japanese Regulatory Approval for BRACAnalysis CDx®

Nov 07, 2016 | Products

The GeneSight® Precision Medicine Test Drives Significant Medication Cost Savings in Patients with Generalized Anxiety Disorder

Nov 04, 2016 | Products

Myriad Genetics Reports Fiscal First-Quarter 2017 Financial Results

Nov 01, 2016 | Financial

The Myriad myPath® Melanoma Test Effectively Diagnosed Patients in the Largest Outcomes-Based Study for a Melanoma Diagnostic

Oct 27, 2016 | Products

Myriad's BRACAnalysis CDx® Test Identifies Patients with Ovarian Cancer Who Would Benefit from Second-Line Maintenance Treatment with Olaparib

Oct 26, 2016 | Products

Myriad RBM Announces an Agreement with Sanofi to Measure Predictive Cardiovascular Biomarkers in Patients with Diabetes

Oct 25, 2016 | Products

Myriad Genetics Inc. Forms Relationship with ION Solutions to Deliver Quality Hereditary Cancer Tests and Services to the Nation's Largest Network of Community Oncologists

Oct 21, 2016 | Corporate

Myriad to Announce Fiscal First-Quarter 2017 Financial Results on November 1

Oct 20, 2016 | Corporate

Myriad Genetics Teams Up with Project BioEYES to Advance STEM Education in Utah

Oct 18, 2016 | Corporate

Myriad Will Present New Data on Its Variant Classification Program at the ASHG Annual Meeting

Oct 17, 2016 | Products

Myriad's myChoice® HRD Test Identifies Patients with Ovarian Cancer Who May Benefit from Treatment with Niraparib

Oct 08, 2016 | Products

Myriad Announces Four Poster Presentations at the 2016 European Society for Medical Oncology (ESMO) Annual Meeting

Oct 07, 2016 | Products

The US Oncology Network Selects Myriad Genetics as Preferred Provider for Hereditary Cancer Testing

Oct 04, 2016 | Corporate

CORRECTED: Crescendo Bioscience Announces Four Poster Presentations at the American College of Rheumatology 2016 Annual Meeting

Oct 03, 2016 | Products

Crescendo Bioscience Announces Four Poster Presentations at the American College of Rheumatology 2016 Annual Meeting

Oct 03, 2016 | Products

Myriad Appoints Chip Parkinson as EVP for Reimbursement Strategy

Sep 29, 2016 | Corporate

Myriad to Present New myRisk Hereditary Cancer Data Further Demonstrating the Benefits of Gene Panel Testing

Sep 26, 2016 | Products

Myriad RBM's TruCulture® and Gene Expression Profiling Characterizes Immune Responses in Landmark Study Led by Institut Pasteur

Sep 07, 2016 | Pipeline

Myriad Genetics Completes Acquisition of Assurex Health

Sep 01, 2016 | Corporate

Myriad Genetics to Present at the 2016 Morgan Stanley Global Healthcare Conference

Aug 30, 2016 | Corporate

Myriad Genetics Reports Fiscal Fourth-Quarter 2016 Financial Results

Aug 09, 2016 | Financial

Myriad Genetics Signs Definitive Agreement to Acquire Assurex Health

Aug 03, 2016 | Corporate

Myriad to Announce Fiscal Fourth-Quarter 2016 Financial Results on August 9

Jul 26, 2016 | Financial

Myriad Announces Positive Results for an EndoPredict® Clinical Study Published in the Journal of the National Cancer Institute

Jul 11, 2016 | Products

Myriad's myChoice® HRD Test Successfully Identifies Patients that Meet Primary Endpoint in TESARO's Pivotal Phase 3 Ovarian Cancer Study with Niraparib

Jun 29, 2016 | Products

Crescendo Bioscience Announces that New Data on Vectra® DA Will Be Presented at the European League Against Rheumatism 17th Annual Congress

Jun 10, 2016 | Products

Myriad Board Approves $200 Million Increase in Share Repurchase Program

Jun 07, 2016 | Corporate

Myriad myRisk® Hereditary Cancer Test Demonstrates the Magnitude of Breast and Ovarian Cancer Risk in Nearly 100,000 Patients

Jun 06, 2016 | Products

Myriad Genetics to Present at the 2016 Goldman Sachs Healthcare Conference

Jun 06, 2016 | Corporate

Myriad Will Present Three New Hereditary Cancer Studies at the ASCO Annual Meeting

Jun 05, 2016 | Products

Myriad Acquires Sividon Diagnostics

May 31, 2016 | Corporate

Myriad Genetics' Statement on HIPAA Complaint from Four Patients

May 19, 2016 | Corporate

Myriad Announces Plans to Launch a Web Portal for Patients that Will Provide Access to Test Results, Tools and Health Information

May 18, 2016 | Corporate

Myriad to Present New Research at the 2016 ASCO Annual Meeting

May 18, 2016 | Products

Crescendo Bioscience Launches Web Portal for Patients with Rheumatoid Arthritis

May 11, 2016 | Products

Myriad to Present Three New Studies at the AUA Annual Meeting

May 06, 2016 | Products

Myriad Genetics Reports Fiscal Third-Quarter 2016 Financial Results

May 03, 2016 | Financial

Myriad Genetics to Present at the Bank of America Health Care Conference

May 02, 2016 | Corporate

Myriad to Announce Fiscal Third-Quarter 2016 Financial Results on May 3

Apr 22, 2016 | Financial

Myriad Genetics Announces Presentations at the 2016 American Association for Cancer Research Annual Meeting

Apr 14, 2016 | Products

Myriad myRisk® Hereditary Cancer Article in Journal of Clinical Oncology Highlights Importance of Expanding Genetic Testing for Breast Cancer Patients

Mar 30, 2016 | Products

Myriad Genetics Teams Up with Access Health® to Educate the Public about Hereditary Cancer and Genetic Testing

Mar 21, 2016 | Products

The Myriad myRisk® Hereditary Cancer Test Identifies 60 Percent More Deleterious Mutations in Patients with Endometrial Cancer

Mar 18, 2016 | Products

Myriad Presents Second Pivotal Validation Study for Its myPath® Melanoma Test

Mar 15, 2016 | Products

Myriad Genetics to Present at the Barclays Capital 2016 Global Healthcare Conference

Mar 08, 2016 | Corporate

Myriad Advances Proprietary myVision® Variant Classification Tools to a Broader Range of Cancer Risk Genes

Mar 08, 2016 | Products

Myriad Genetics Expands Strategic Research Collaboration With AbbVie

Feb 23, 2016 | Products

Myriad Expands Diagnostic Research Collaboration With TESARO and Merck

Feb 22, 2016 | Products

Myriad Genetics Reports Fiscal Second-Quarter 2016 Financial Results

Feb 02, 2016 | Financial

Myriad to Announce Fiscal Second-Quarter 2016 Financial Results on February 2

Jan 21, 2016 | Financial

DAY HIGH

YEAR HIGH

DAY LOW

YEAR LOW

News Releases

Select year

Categories

Myriad Genetics to Present at the 2017 JP Morgan Healthcare Conference

Positive Clinical Utility Results of Crescendo's Vectra® DA Test for Rheumatoid Arthritis Published in the Journal Arthritis & Rheumatology

United Rheumatology Issues Clinical Practice Guidelines and Recommends the Vectra® DA Test for Adults with Rheumatoid Arthritis

The EndoPredict® Test Significantly Outperforms the First-Generation Test in Predicting the Risk of Node-Negative and Node-Positive Breast Cancer Recurrence

Myriad Genetics Will Present Results from Six Breast Cancer Studies at SABCS

Crescendo Bioscience Announces Four Studies with Vectra® DA Will Be Presented at the American College of Rheumatology 2016 Annual Meeting

Myriad Will Seek Japanese Regulatory Approval for BRACAnalysis CDx®

The GeneSight® Precision Medicine Test Drives Significant Medication Cost Savings in Patients with Generalized Anxiety Disorder

Myriad Genetics Reports Fiscal First-Quarter 2017 Financial Results

The Myriad myPath® Melanoma Test Effectively Diagnosed Patients in the Largest Outcomes-Based Study for a Melanoma Diagnostic

Myriad's BRACAnalysis CDx® Test Identifies Patients with Ovarian Cancer Who Would Benefit from Second-Line Maintenance Treatment with Olaparib

Myriad RBM Announces an Agreement with Sanofi to Measure Predictive Cardiovascular Biomarkers in Patients with Diabetes

Myriad Genetics Inc. Forms Relationship with ION Solutions to Deliver Quality Hereditary Cancer Tests and Services to the Nation's Largest Network of Community Oncologists

Myriad to Announce Fiscal First-Quarter 2017 Financial Results on November 1

Myriad Genetics Teams Up with Project BioEYES to Advance STEM Education in Utah

Myriad Will Present New Data on Its Variant Classification Program at the ASHG Annual Meeting

Myriad's myChoice® HRD Test Identifies Patients with Ovarian Cancer Who May Benefit from Treatment with Niraparib

Myriad Announces Four Poster Presentations at the 2016 European Society for Medical Oncology (ESMO) Annual Meeting

The US Oncology Network Selects Myriad Genetics as Preferred Provider for Hereditary Cancer Testing

CORRECTED: Crescendo Bioscience Announces Four Poster Presentations at the American College of Rheumatology 2016 Annual Meeting

Crescendo Bioscience Announces Four Poster Presentations at the American College of Rheumatology 2016 Annual Meeting

Myriad Appoints Chip Parkinson as EVP for Reimbursement Strategy

Myriad to Present New myRisk Hereditary Cancer Data Further Demonstrating the Benefits of Gene Panel Testing

Myriad RBM's TruCulture® and Gene Expression Profiling Characterizes Immune Responses in Landmark Study Led by Institut Pasteur

Myriad Genetics Completes Acquisition of Assurex Health

Myriad Genetics to Present at the 2016 Morgan Stanley Global Healthcare Conference

Myriad Genetics Reports Fiscal Fourth-Quarter 2016 Financial Results

Myriad Genetics Signs Definitive Agreement to Acquire Assurex Health

Myriad to Announce Fiscal Fourth-Quarter 2016 Financial Results on August 9

Myriad Announces Positive Results for an EndoPredict® Clinical Study Published in the Journal of the National Cancer Institute

Myriad's myChoice® HRD Test Successfully Identifies Patients that Meet Primary Endpoint in TESARO's Pivotal Phase 3 Ovarian Cancer Study with Niraparib

Crescendo Bioscience Announces that New Data on Vectra® DA Will Be Presented at the European League Against Rheumatism 17th Annual Congress

Myriad Board Approves $200 Million Increase in Share Repurchase Program

Myriad myRisk® Hereditary Cancer Test Demonstrates the Magnitude of Breast and Ovarian Cancer Risk in Nearly 100,000 Patients

Myriad Genetics to Present at the 2016 Goldman Sachs Healthcare Conference

Myriad Will Present Three New Hereditary Cancer Studies at the ASCO Annual Meeting

Myriad Acquires Sividon Diagnostics

Myriad Genetics' Statement on HIPAA Complaint from Four Patients

Myriad Announces Plans to Launch a Web Portal for Patients that Will Provide Access to Test Results, Tools and Health Information

Myriad to Present New Research at the 2016 ASCO Annual Meeting

Crescendo Bioscience Launches Web Portal for Patients with Rheumatoid Arthritis

Myriad to Present Three New Studies at the AUA Annual Meeting

Myriad Genetics Reports Fiscal Third-Quarter 2016 Financial Results

Myriad Genetics to Present at the Bank of America Health Care Conference

Myriad to Announce Fiscal Third-Quarter 2016 Financial Results on May 3

Myriad Genetics Announces Presentations at the 2016 American Association for Cancer Research Annual Meeting

Myriad myRisk® Hereditary Cancer Article in Journal of Clinical Oncology Highlights Importance of Expanding Genetic Testing for Breast Cancer Patients

Myriad Genetics Teams Up with Access Health® to Educate the Public about Hereditary Cancer and Genetic Testing

The Myriad myRisk® Hereditary Cancer Test Identifies 60 Percent More Deleterious Mutations in Patients with Endometrial Cancer

Myriad Presents Second Pivotal Validation Study for Its myPath® Melanoma Test

Myriad Genetics to Present at the Barclays Capital 2016 Global Healthcare Conference

Myriad Advances Proprietary myVision® Variant Classification Tools to a Broader Range of Cancer Risk Genes

Myriad Genetics Expands Strategic Research Collaboration With AbbVie

Myriad Expands Diagnostic Research Collaboration With TESARO and Merck

Myriad Genetics Reports Fiscal Second-Quarter 2016 Financial Results

Myriad to Announce Fiscal Second-Quarter 2016 Financial Results on February 2

Myriad Advances Prostate and Renal Cancer Molecular Diagnostic Tests at the 2016 ASCO Genitourinary Cancers Symposium

Myriad Genetics to Present at the 34th Annual J.P. Morgan Healthcare Conference